Home' Australian Pharmacist : Australian Pharmacist May 2014 Contents Australian Pharmacist May 2014 I ©Pharmaceutical Society of Australia Ltd. 35
major cities of Tasmania -- Hobart and
Launceston. Thirteen Hobart RACFs were
recruited as the intervention group,
with 12 Launceston RACFs acting as the
control group. A series of QUM strategies
were offered in all intervention RACFs,
including three dedicated psychotropic
medication audits and feedback, nurse
education, GP detailing, the promotion
of 'good practice' guidelines and
information brochures for relatives and
an interdisciplinary sedative review
process. The principle strategies of the
RedUSe trial are illustrated below.
The RedUSe trial was designed and
administered by the Unit of Medication
Outcomes, Research and Education
(UMORE) at the University of Tasmania,
and was funded by the Australian
Government Department of Health and
Ageing as part of the Fourth Community
By the conclusion of the RedUSe trial,
benzodiazepine use was significantly
reduced in intervention facilities (33% to
26%, p < 0.005), whereas use increased
in the control sites. Antipsychotic use
was significantly reduced in intervention
RACFs compared to control facilities,
although to a lesser extent than
benzodiazepines (21% to 18%, p < 0.05).
Over the six months of the intervention
project, the proportion of dose
reductions of both benzodiazepines and
antipsychotics in intervention RACFs
was more than double the proportion
recorded in control facilities. In addition,
the rate of new psychotropic prescribing
was significantly less in intervention
These findings suggest that QUM
strategies coordinated through
community pharmacies offer
an effective approach to reduce
antipsychotic and benzodiazepine use
RedUSe national extension
In May 2013 UMORE obtained funding
to extend the RedUSe project nationally
as part of the Aged Care Service
Improvement and Healthy Ageing Grant
Fund administered by the Australian
Government Department of Health and
Ageing (now the Department of Social
Services). Independent external reviews
of all project training and educational
material, plus the involvement of NPS
MedicineWise and the Pharmaceutical
Society of Australia, will ensure that
the project's quality use of medicines
information is relevant and consistent
with current professional guidance.
The RedUSe project expansion will
involve 150 RACFs across six states,
their staff, GPs, the supply community
pharmacy, as well as the pharmacist
providing the QUM services for the
RACF. The project will be rolled out in
three phases, with the first rollout in
30 RACFs in Western Australia, South
Australia and Victoria starting in March
2014. The response from RACFs has
been exceptional, with expressions of
interest from over 250 facilities wanting
to be involved.
The ultimate benefits for older people in
RACFs following successful reduction in
rates of psychotropic use should include
increased mobility and alertness,
decreased fall rate and improved
well-being. As very few medication
management intervention projects
have assessed these types of outcomes,
the RedUSe research team at UMORE
aims to evaluate the impact of reducing
psychotropic medication use on various
resident clinical measures and their
quality of life.
For more information on the RedUSe
project email: RedUSe.email@example.com.
au or call: 1800 827 864.
1. Beers M, et al. Psychoactive medication use in
intermediate-care facility residents. JAMA. 1988;
2. Ruths S, et al. Trends in psychotropic drug prescribing
in Norwegian nursing homes from 1997 to 2009: a
comparison of six cohorts. International Journal of
Geriatric Psychiatry 2013; 28(8):868--76.
3. Snowdon J et al. Psychotropic drug use in Sydney nursing
homes. MJA. 1995;163:70--2.
4. Briesacher B et al. The quality of antipsychotic drug
prescribing in nursing homes. Archives of Internal
5. Schneider L et al.Efficacy and adverse effects of atypical
antipsychotics for dementia: Meta-analysis of randomised,
placebo-controlled trials. American Journal of Geriatric
6. Madhusoodanan S, Bogunovic O. Safety of
benzodiazepines in the geriatric population. Expert
Opinion Patient Safety. 2004;3(5):485--93.
7. Centers for Medicare and Medicaid Services. Interpretive
guidelines for long-term care facilities. In :State Operations
Manual Baltimore, Md:.Baltimore, Md: Centers for Medicare
and Medicaid Services. Dec18, 2006 appendix PP.
8. Banerjee S. The use of antipsychotic medication for people
with dementia: Time for action. Report to the minister for
9. Australian Senate. Psychotherapeutic medication
in Australia: report of the Senate Community Affairs
References Committee. (1995) Canberra. Australian
Government Printing Service. 1995.
10. NSW Health. Report on Psychotropic medication use in
nursing homes: NSW Ministerial Taskforce,1997.
11. Roberts M et al. Outcomes of a randomised controlled trial
of a clinical pharmacy intervention in 52 nursing homes.
British Journal of Clinical Pharmacology. 2001;51:25765.
12. Pharmaceutical Society of Australia. Guidelines
for pharmacists providing Residential Medication
Management Review (RMMR) and Quality Use of
Medicines (QUM) services. Oct 2011.
13. Westbury J et al. An effective approach to reduce
the use of antipsychotic and benzodiazepines: The
RedUSe project. International Psychogeriatrics 2010
"THE REDUCING USE OF
SEDATIVES REDUSE TRIAL
AIMED TO EVALUATE IF
STRATEGIES COULD POSITIVELY
INFLUENCE RACF PSYCHOTROPIC
Links Archive Australian Pharmacist April 2014 Australian Pharmacist June 2014 Navigation Previous Page Next Page